Category Archives: News

Crohn’s disease is a chronic relapsing auto-inflammatory condition of the gastrointestinal tract that primarily affects young individuals with an increasing incidence rate. There is still no cure for Crohn’s disease and current treatment-options are li… Continue reading →

To assess the initial and long-term maintenance dosing of biologic medications in pediatric UC and CD patients, using data in the ICN registry. Continue reading →

A significant proportion of patients with ulcerative colitis (UC) have suboptimal responses to medical therapy. Expansion of regulatory T cells (Tregs), but not conventional T cells (Tcons), through the use of low doses (LD) of the T cell growth factor… Continue reading →

Despite highly effective therapies, many children develop medically refractory ulcerative colitis (UC) and undergo proctocolectomy with ileal pouch anal anastomosis (IPAA). There is little real world evidence regarding IPAA outcomes in pediatric UC pat… Continue reading →

The receptor for advanced glycation end products (RAGE), a pattern recognition receptor, plays a role in chronic inflammation. Abrogation of proinflammatory RAGE signaling by ligand binding (e.g., S100/calgranulins) to soluble RAGE decoy (sRAGE) is a p… Continue reading →

Non-alcoholic fatty liver disease (NAFLD) is the fastest growing cause of chronic liver disease among patients with inflammatory bowel diseases (IBD). Studies have suggested that patients with IBD develop NAFLD with fewer metabolic risk factors than th… Continue reading →

Data describing the effect of obesity on anti-TNF treatment response in inflammatory bowel disease (IBD) are conflicting. This likely reflects the shortcomings of using body mass index (BMI) to capture an individual’s adipose stores. Recent studies hav… Continue reading →

25% of children hospitalized with acute severe ulcerative colitis (ASUC) rescued with infliximab (IFX) at labeled dosing undergo a colectomy prior to discharge. Our aim was to determine whether IFX pharmacokinetics (PK) are associated with treatment re… Continue reading →

The use of opioids among patients with inflammatory bowel disease (IBD) in the United States is increasing and it is associated with higher mortality, re-admissions, healthcare utilization, and disability. The American Gastroenterological Association’s… Continue reading →

Irregular CD4+ effector T cell responses play an essential role in the intestinal inflammation, while IL-10 produced by effector T cells limits their pathogenesis to maintain the intestinal homeostasis. Dietary free fatty acids are actively involved in… Continue reading →